Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Phaeno Therapeutics Co., Ltd.

Chengdu Jinrui Foundation Biotech Co., Ltd.

Cms Research & Development Pte. Ltd.

Cstone Pharmaceuticals Co., Ltd.

Boyu Hu

Shuhui Chen

Kevin X Chen

Kai Zhou

Yanxin Yu

Jian Li

Fang Liu

Zhaoguo Chen

Minliang Xiao

Charles Z Ding

Cheng Li

Xiquan Zhang

Guoping Hu

Hongjiang Xu

Jian Xiong

Xin Tian

Cheng Xie

Jingjing Wang

Zhigang Huang

Xiaofei Wang

Haizhong Tan

Xiawei Wei

Xinde Chen

Linghui Wu

Xiangjian Wang

Ruibin Lin

Fen Jiang

Bin Liu

Jinsheng Xie

Xiaoyuan Chen

Jiangfeng Lin

Haomin Chen

Huiyu Zhang

The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors. 

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an Areceptor. 

Fused ring derivative as Areceptor inhibitor

A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug. 

Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof

Disclosed in the present invention is a type of novel &#x3b2;-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. 

&#x3b2;-lactamase inhibitors

Growing community of inventors

Shanghai, China

Boyu Hu